SLC5A2 and type 2 diabetes mellitus: Metformin has been associated with positive effects in HF, certain DPP-4 inhibitors (saxagliptin) and thiazolidinediones are not recommended and the evidence for GLP-1 agonists is inconclusive while results from four large-scale clinical trials of >36,000 patients with T2D suggest that SGLT2 inhibitors have a role in the prevention of HF [39].